BPS804
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteogenesis Imperfecta
Conditions
Osteogenesis Imperfecta
Trial Timeline
Oct 31, 2017 → Nov 1, 2018
NCT ID
NCT03216486About BPS804
BPS804 is a phase 2 stage product being developed by Ultragenyx Pharmaceutical for Osteogenesis Imperfecta. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03216486. Target conditions include Osteogenesis Imperfecta.
What happened to similar drugs?
1 of 7 similar drugs in Osteogenesis Imperfecta were approved
Approved (1) Terminated (2) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216486 | Phase 2 | Withdrawn |
| NCT01417091 | Phase 2 | Completed |
Competing Products
16 competing products in Osteogenesis Imperfecta
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide (FORTEO) + Placebos | Eli Lilly | Approved | 43 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Phase 3 | 40 |
| Romosozumab + Bisphosphonate | Amgen | Phase 3 | 47 |
| Romosozumab | Amgen | Phase 1 | 29 |
| Denosumab | Amgen | Phase 3 | 32 |
| Denosumab + Alternative osteoporosis medications | Amgen | Phase 3 | 32 |
| Fresolimumab | Sanofi | Phase 1 | 29 |
| SAR439459 + Placebo | Sanofi | Phase 1 | 21 |
| BPS804 | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2/3 | 36 |
| Setrusumab | Ultragenyx Pharmaceutical | Phase 2 | 21 |
| setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |
| setrusumab + zoledronic acid (optional) | Ultragenyx Pharmaceutical | Phase 2 | 29 |
| Bisphosphonate + Setrusumab | Ultragenyx Pharmaceutical | Phase 3 | 38 |